

## Evaluation of hsCRP, Insulin and Insulin resistance in Polycystic Ovarian Syndrome

Sapna Jangir<sup>1,\*</sup>, Jairam Rawtani<sup>2</sup>

<sup>1</sup>P.G. Student, <sup>2</sup>Professor, Dept. of Biochemistry, Dr. S. N. Medical College, Jodhpur, Rajasthan

**\*Corresponding Author:**

Email: sapnajangir24@gmail.com

### Abstract

**Introduction:** Polycystic Ovarian Syndrome consists of a constellation of metabolic abnormalities and is now well recognised having a major effect throughout life on the reproductive, metabolic and cardiovascular health of affected women.

**Objective:** The present study was conducted to evaluate hsCRP, insulin and insulin resistance levels in PCOS patients.

**Materials and Method:** 30 PCOS subjects in the age group of 18 to 34 years and 25 age-matched healthy women as controls were evaluated.

**Result:** Serum hsCRP, insulin, insulin resistance, BMI and waist-to-hip ratio were significantly elevated ( $p < 0.0001$ ) in PCOS cases when compared with controls. There was a positive correlation between hsCRP and insulin ( $p = 0.2001$ ) and hsCRP and insulin resistance ( $p = 0.127$ ) in PCOS patients.

**Conclusion:** PCOS women have added risk of complications of cardiovascular disease and Diabetes mellitus.

**Keywords:** Cardiovascular disease, Diabetes mellitus, hsCRP, Insulin resistance, Polycystic Ovarian Syndrome, Inflammation.

### Introduction

Polycystic Ovarian Syndrome (PCOS) is a heterogeneous endocrine disorder with diverse clinical presentation affecting 5-10% women of reproductive age worldwide.<sup>(1)</sup> It is a multifactorial and polygenic condition. In 1935, Irving F. Stein and Michael L. Leventhal first described PCOS (That is also known as "Stein-Leventhal" syndrome) as a symptom complex associated with anovulation.<sup>(2)</sup> The short term consequences of PCOS include irregular menses, obesity, infertility, hirsutism, acne/androgenic alopecia, glucose intolerance/acanthosis nigricans and long term deleterious effects of PCOS are Diabetes Mellitus,<sup>(3)</sup> dyslipidaemia,<sup>(4)</sup> endometrial and breast cancer,<sup>(5)</sup> hypertension<sup>(6)</sup> and Cardiovascular disease.<sup>(7)</sup> The endocrine milieu in women with PCOS reflects multiple potential aetiologies with abnormal gonadotropin secretion,<sup>(8)</sup> genetic factor,<sup>(9)</sup> hyperinsulinemia and insulin resistance.<sup>(10)</sup> PCOS is characterized by a metabolic disorder in which hyperinsulinemia and peripheral insulin resistance are central features.<sup>(11)</sup> The risk of type 2 diabetes mellitus among PCOS patients is 5 to 10-fold higher than normal.<sup>(12)</sup> Insulin has direct and indirect roles in the pathogenesis of hyper androgenism in PCOS. Insulin in collaboration with LH (luteinizing hormone) enhances the androgen production of theca cells.<sup>(13)</sup> Insulin resistance (IR) is an insufficient response of target tissues such as liver, skeletal muscle and adipose tissues to the physiological plasma insulin levels.<sup>(14)</sup> Insulin resistance and compensatory hyperinsulinemia have implications for both ovarian function (amplifying androgen excess and inhibiting ovulation) and long-term health. C-reactive protein is an acute-phase reactant synthesized by the liver in response to proinflammatory cytokines released by damaged

tissue.<sup>(15)</sup> PCOS is a pro-inflammatory disorder (as evidenced by elevated plasma concentrations of hsCRP) characterized by the presence of chronic low-grade inflammation, insulin resistance, obesity and type 2 Diabetes mellitus.<sup>(16)</sup> Women with PCOS with the highest baseline high sensitive-CRP (hs-CRP) levels had a five times greater risk of suffering a vascular event and seven times the risk of myocardial infarction or stroke than control subjects.<sup>(17)</sup>

The aim of this study was to estimate the levels of hsCRP, insulin and IR in PCOS patients and to explore the utility of these parameters in the early diagnosis and better management of PCOS and related abnormalities and in prevention of long term risks.

### Materials and Method

The study was carried out on 30 PCOS subjects in the age group of 18 to 34 years and 25 age-matched healthy women as controls. The study was conducted at Dr. S.N. Medical College and its associated group of Hospitals, Jodhpur. PCOS was diagnosed based on the Rotterdam ESHRE/ASRM revised consensus 2003.<sup>(18)</sup> As per the criteria any two out of the following three criteria should present to diagnose PCOS.

- Oligo and /or anovulation.
- Clinical and /or biochemical sign of hyperandrogenism.
- Polycystic ovaries (by Ultrasonography).

Anthropometric measurement including height, weight, BMI, waist circumference, hip circumference and Waist-to-Hip Ratio were included as methodology. Blood sugar, serum insulin and hsCRP were measured in all subjects from morning blood sample collected after 12 hours of fasting. Blood glucose and serum insulin was measured. Insulin resistance was calculated.


**Statistical Analysis:** Statistical analysis was performed using SPSS software. For all the continuous variables the results are given in mean ± standard deviation. The magnitude of inter group differences for each of the parameters was quantified by using student’s compute ‘t’ test values (Student’s ‘t’ test) and ‘r’ values (Pearson’s coefficient of correlation). On the basis of t-values and r-values ‘p’ values (probability) were determined. Probability value p<0.05 was considered for statistical significance.

**Results**

Age, BMI, WHR and biochemical parameters of the PCOS subjects and controls are given in Table 1. Age of PCOS subjects and controls show significantly increase. BMI and WHR are highly significantly elevated in PCOS subjects than controls. Significantly elevated fasting plasma glucose is seen in PCOS subjects as compared to controls. Fasting insulin, IR and hsCRP are highly significantly increased in PCOS subjects than controls. Correlation analysis reveals significant positive correlation of insulin with glucose, BMI and IR and non-significant positive correlation of hsCRP with insulin and IR in PCOS patients (Table 2).

**Table 1: Comparison of age, BMI, WHR and biochemical parameters in PCOS subjects and controls**

Parameter	Controls (Mean±SD)	PCOS subjects (Mean±SD)	p value
Age (years)	23.2±4.44	26±4.3	0.015
BMI (kg/ m <sup>2</sup> )	21.41±0.80	24.62±2.82	<0.0001
WHR	0.78±0.02	0.89±0.05	<0.0001
Fasting plasma glucose (mg/dl)	82.44±8.6	91.86±13.13	0.0030
Fasting insulin (µIU/ml)	10.98±4.43	26.68±9.27	<0.0001
HOMA-IR	2.25±1.0	6.21±2.64	<0.0001
hsCRP (mg/l)	0.87±0.11	3.67±0.67	<0.0001



**Fig. 1: Comparison of biochemical parameters in PCOS and Healthy controls**

**Table 2: Correlation among PCOS subjects**

Variables	PCOS subjects Pearson correlation (r value)	p value
Insulin and Glucose	0.3038	0.0899
Insulin and BMI	0.7983	0.001
Insulin and HOMA-IR	0.9323	<0.0001
hsCRP and Insulin	0.1803	0.2001
hsCRP and HOMA-IR	0.1219	0.127

**Discussion**

Polycystic Ovarian Syndrome has an important component of metabolic dysfunction central to which is insulin resistance and associated hyperinsulinemia. In PCOS, Insulin resistance (due to impairment in anti-lipolytic function of insulin) and hyperandrogenism (by decreasing lipoprotein lipase activity) contribute to cardiovascular dysfunction. A powerful predictive relationship exists between elevated CRP production and cardiovascular risk. Elevated CRP level is the main factor that indicate the development of inflammation in PCOS. Thus consequences of PCOS extend beyond the reproductive axis and PCOS is associated with comorbidities including obesity, hypertension, Cardiovascular disease, endometrial and breast cancer, pregnancy related complication and obstructive sleep apnea.

Polycystic ovarian syndrome throughout the life:		
Adolescents	Reproductive phase	Post menopause
Insulin Resistance		
Obesity		
Oligo-menorrhoea/Amenorrhoea		Type 2 Diabetes Mellitus
Hirsutism		Dyslipidemia
Acne	Impaired glucose tolerance	
	Infertility	Hypertension
	Gestational diabetes	Cardiovascular disease
	Complication in pregnancy	Hypercholesterolemia

Our results are in accordance with the study of Dehdashtihaghighat S et al they observed a highly significant increase in fasting serum insulin and insulin resistance in PCOS subjects as compared with healthy control subjects.<sup>(20)</sup> Puder JJ and Varga S et al also showed in their study that women with PCOS were more insulin resistant compared to BMI matched controls.<sup>(21)</sup> In our study, we observed significantly high levels of serum hsCRP are significantly increased in (p<0.0001) in PCOS subjects than controls. Sumitra NUC et al suggest that oxidative stress is present in women with PCOS along with elevated hsCRP which indicate that these women are at high risk for developing

cardiovascular disease.<sup>(22)</sup> Our results are in agreement with the studies of Sharma P et al and Ahmed M M et al in their study hsCRP levels were significantly higher ( $p > 0.0001$ ) in women with PCOS compared with control and concluded that inflammatory activity is increased in women with PCOS that can lead to an increased risk for atherosclerosis.<sup>(23,24)</sup> Correlation analysis in our study showed that insulin levels were significantly positively correlated with glucose ( $r = 0.3038$ ,  $p = 0.0899$ ), BMI ( $r = 0.7933$ ,  $p = 0.001$ ) and IR ( $r = 0.9323$ ,  $p < 0.0001$ ). hsCRP levels were non-significant positively correlated with insulin ( $r = 0.1803$ ,  $p = 0.2001$ ) and IR ( $r = 0.1219$ ,  $p = 0.127$ ).

### Conclusion

Both Insulin resistance and low-grade chronic inflammation are predictor of Cardiovascular diseases in women with Polycystic Ovarian Syndrome. The evaluation of Body Mass Index, Waist-to-Hip Ratio, Insulin, Insulin Resistance and hsCRP routinely in PCOS patients may have diagnostic role in the early detection of metabolic abnormalities and endocrine derangements and timely management of these alterations can prevent the risk sequelae of co-morbid Diabetes and Cardiovascular disease in Polycystic Ovarian Syndrome females.

### References

1. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC et al. Androgen excess in women: experience with over 1000 consecutive patients. *J Clin Endocrinol Metab* 2004;89:453.
2. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. *Am J Obstet Gynecol* 1935;29:181.
3. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normo-glycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. *Hum Reprod* 2001;16:1995.
4. Wild S, Pierpoint T, Jacobs H, et al. Long term consequences of polycystic ovary syndrome and risk of gynaecological cancer: a systematic review. *Reprod BioMed Online* 2010;19:398-405.
5. Brinton LA, Moghissi KS, Westhoff CL, et al. Cancer risk among infertile women with androgen excess or menstrual disorders (including PCOS). *Fertil Steril* 2010;94:1787-92.
6. Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine and metabolic features in women with previous gestational diabetes mellitus. *J Clin Endocrinol Metab* 1998;83:1143.
7. Luque-Ramirez M, Alvarez-Blasco F, et al. Obesity is the major determinant of the abnormalities in blood pressure found in young women with the PCOS. *J Clin Endocrinol Metab* 2007;92(6):2141-48.
8. Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. *J Clin Endocrinol Metab* 1970;30(4):435-42.
9. Glinborg D, Andersen M. An update on the pathogenesis, inflammation and metabolism in hirsutism and polycystic ovary syndrome. *Gynecol Endocrinol* 2010;26:281-96.
10. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. *J Clin Endocrinol Metab* 1998;83:2001-5.
11. Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine and metabolic features in women with previous gestational diabetes mellitus. *J Clin Endocrinol Metab* 1998;83:1143.
12. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome and type 2 diabetes mellitus. *Fertil Steril* 2002;77(6):1095-105.
13. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2005;90(1):66-71.
14. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine. Mc Graw Hill 2012; 18th Ed: (243):2972.
15. Murry RK, Bender DA, Botham KM, Kennelly PJ, Rodwell VW, Weil PA. Harper's illustrated biochemistry. Mc Graw Hill 2009; 28<sup>th</sup> Ed: (50):568.
16. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and meta-analysis. *Fertil Steril* 2011;95:1048-58.
17. Sarwar N, Thompson AJ, Di Angelantonio E. Markers of inflammation and risk of coronary heart disease. *Disease Markers* 2009;26:217-25.
18. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS. *Hum Reprod* 2004;19:41.
19. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. *Endocr Rev* 1997;18(6):774-800.
20. Dehdashtihaghighat S, Abolfazl Mehdizadehkashi, Amirmohsen Arbabi, Mohadeseh Pishgahroudsari, Shahla Chaichian. Assessment of C - reactive protein and C3 as Inflammatory Markers of Insulin Resistance in Women with Polycystic Ovary Syndrome: A Case-Control Study. *J Reprod Infertil* 2013;14(4):197-201.
21. Puder JJ, Varga S, et al. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. *J Clin Endocrinol Metab* 2005;90(11):6014-21.
22. Sumitra NUC, Lakshmi RL, Menon NL, Subhakumari KN, Sheejamol VS. Evaluation of Oxidative Stress and hsCRP in PoCOS in a Tertiary Care Hospital. *International Journal of Pharma Sciences* 2013;3(5):350-55.
23. Sharma P, Gupta A, Purohit P. Cardiovascular Risk Factors Insulin Resistance [IR], High Sensitivity C-reactive Protein (hs-CRP) and Fibrinogen in Pre-Menopausal women with Poly cystic ovarian syndrome (PCOS). *Journal of Cardiovascular Disease Research* 2015;6:67-71.
24. Ahmed MM, Fawzia AH, Abdulrahman AA. Cardiovascular disease markers in women with polycystic ovary syndrome with emphasis on asymmetric dimethylarginine and homocysteine. *Ann Saudi Med* 2010;30(4):278-83.